Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.190
+0.240 (8.14%)
At close: Dec 20, 2024, 4:00 PM
3.400
+0.210 (6.58%)
After-hours: Dec 20, 2024, 6:17 PM EST
Cyclerion Therapeutics Revenue
Cyclerion Therapeutics had revenue of $194.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $194.00K.
Revenue (ttm)
$194.00K
Revenue Growth
n/a
P/S Ratio
41.05
Revenue / Employee
$194,000
Employees
1
Market Cap
8.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Meihua International Medical Technologies | 94.25M |
XWELL | 33.83M |
Precipio | 17.41M |
Dominari Holdings | 12.59M |
NeuroMetrix | 3.77M |
RedHill Biopharma | 3.71M |
Elevai Labs | 2.45M |
CYCN News
- 4 days ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 4 months ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 1 year ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire
- 1 year ago - Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewsWire
- 1 year ago - Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewsWire
- 1 year ago - Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 1 year ago - Cyclerion Announces Reverse Stock Split - GlobeNewsWire
- 1 year ago - Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewsWire